
https://www.wired.com/story/drugs-aging-medicine-biotech/
Jan 4, 1:44pm: The FDA will approve a drug for the treatment of senesense (aging) before the end of the decade (before 2030) → The FDA will approve a drug for the treatment of senescence (aging) before the end of the decade (before 2030)
People are also trading
One distinction that matters for resolution: FDA's human side (CDER) has no aging indication, but FDA's veterinary side (CVM) already accepted lifespan extension as an indication for a dog drug in 2023 and accepted its safety package in January 2026. If this market means human approval, that's the relevant contrast; the dog approval is expected to be decided around 2027. I run both halves as separate questions: https://manifold.markets/w0lph/will-the-fda-conditionally-approve and https://manifold.markets/w0lph/will-the-fda-approve-any-drug-for-a